C. Vancheri (Catania (CT), Italy), M. Wijsenbeek (Rotterdam, Netherlands)
What can we learn from Idiopathic Pulmonary Fibrosis Registries?
T. Lodhi (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), P. Rivera Ortega (Manchester, United Kingdom), H. Morris (Manchester, United Kingdom), T. Marshall (Manchester, United Kingdom), K. Zakis (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), C. Hayton (Manchester, United Kingdom), M. Greaves (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
|     |
Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry
L. Snyder (Durham, North Carolina, United States of America), M. Neely (Durham, North Carolina, United States of America), A. Hellkamp (Durham, North Carolina, United States of America), E. O'Brien (Durham, North Carolina, United States of America), K. Flaherty (Ann Arbor, Michigan, United States of America), J. De Andrade (Birmingham, Alabama, United States of America), C. Conoscenti (Ridgefield, Connecticut, United States of America), T. Leonard (Ridgefield, Connecticut, United States of America), S. Bender (Ridgefield, Connecticut, United States of America), M. Gulati (New Haven, Connecticut, United States of America), D. Culver (Cleveland, Ohio, United States of America), R. Kaner (New York, New York, United States of America), S. Palmer (Durham, North Carolina, United States of America), H. Kim (Minneapolis, Minnesota, United States of America)
| |
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
M. Kreuter (Heidelberg, Germany), H. Kabitz (Konstanz , Germany), L. Hagmeyer (Solingen, Germany), P. Hammerl (Immenhausen, Germany), A. Esselmann (Warendorf, Germany), C. Wiederhold (Fulda, Germany), D. Skowasch (Bonn, Germany), C. Stolpe (Ibbenbüren, Germany), M. Joest (Bonn, Germany), S. Veitshans (Böblingen, Germany), S. Witt (Munich, Germany), R. Leidl (Munich, Germany), A. Hellmann (Augsburg , Germany), M. Pfeifer (Donaustauf, Germany), J. Behr (Munich, Germany), A. Guenther (Gießen, Germany), D. Kauschka (Essen, Germany), F. Herth (Heidelberg, Germany), P. Markart (Fulda, Germany)
| |
The European IPF Registry: Addressing challenges and characteristics of patients with Idiopathic Pulmonary Fibrosis
A. Guenther (Giessen, Germany), E. Krauss (Giessen, Germany), W. Klepetko (Vienna, Austria), P. Bonniaud (Dijon, France), C. Vancheri (Catania, Italy), A. Wells (London, United Kingdom), J. Wagner (Giessen, Germany), B. Paul (Giessen, Germany), U. Costabel (Essen, Germany), M. Nieto Barbero (Madrid, Spain), V. Mueller (Budapest, Hungary), M. Vasakova (Prague, Czech Republic), A. Pesci (Monza, Italy), M. Sofia (Napoli, Italy), F. Drakopanagiotakis (Fulda, Germany), W. Seeger (Giessen, Germany), B. Crestani (Paris, France)
| |
Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry
K. Flaherty (Ann Arbor , United States of America), J. De Andrade (Birmingham, United States of America), L. Lancaster (Nashville, United States of America), S. Limb (South San Francisco, United States of America), K. Lindell (Pittsburgh, United States of America), S. Nathan (Falls Church, United States of America), G. Raghu (Seattle, United States of America), C. Spino (Ann Arbor , United States of America), J. Stauffer (South San Francisco, United States of America), P. Wolters (San Francisco, United States of America), G. Cosgrove (Chicago, United States of America)
| |
Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis
I. Pesonen (Stockholm, Sweden), J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), M. Myllärniemi (Helsinki, Finland), G. Ferrara (Stockholm, Sweden), M. Sköld (Stockholm, Sweden)
| |
Functional decline over time in patients with IPF treated with pirfenidone: the PROOF registry
W. Wuyts (Leuven, Belgium), C. Dahlqvist (Yvoir, Belgium), H. Slabbynck (Antwerp, Belgium), M. Schlesser (Luxembourg City, Luxembourg), N. Gusbin (Liège, Belgium), C. Compere (Brussels, Belgium), S. Maddens (Kortrijk, Belgium), K. Kirchgaessler (Basel, Switzerland), K. Bartley (South San Francisco, CA, United States of America), B. Bondue (Brussels, Belgium)
| |
Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF)
G. Ferrara (Stockholm, Sweden), K. Bartley (South San Francisco, CA, United States of America), A. Levine (Solna, Sweden), L. Arnheim-Dahlstrom (Solna, Sweden), K. Kirchgaessler (Basel, Switzerland), R. Linder (Solna, Sweden), C. Janson (Uppsala, Sweden), C. Sköld (Stockholm, Sweden)
| |
Real world idiopathic pulmonary fibrosis in the EMPIRE registry
M. Vasakova (Prague, Czech Republic), M. Sterclova (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), J. Kus (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hajkova (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Kremer (Tel Aviv, Israel), M. Svoboda (Brno, Czech Republic), M. Janotova (Brno, Czech Republic)
| |
Differences in baseline characteristics of newly diagnosed IPF patents in the EMPIRE countries
V. Müller (Budapest, Hungary), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), J. Kus (Warsaw, Poland), M. Hájková (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Svoboda (Brno, Czech Republic), M. Janotová (Brno, Czech Republic), M. Vašáková (Prague, Czech Republic)
| |
Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE)
A. Kolonics-Farkas (Budapest, Hungary), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), J. Kus (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Kramer (Petah Tikva, Israel), M. Svoboda (Brno, Czech Republic), M. Janotová (Brno, Czech Republic), M. Vašáková (Prague, Czech Republic)
| |
Cryobiopsy in the diagnosis of diffuse parenchymal lung diseases: diagnostic strategy and complications in 699 patients
C. Ravaglia (Forlì, Italy), S. Tomassetti (Forlì, Italy), A. Dubini (Forlì, Italy), S. Piciucchi (Forlì, Italy), V. Poletti (Forlì, Italy)
| |
Combined idiopathic interstitial pneumonia(IIP) and emphysema(E) in the Veterans Administration(VA) health system: characteristics, tobacco Use, and outcomes
R. Pleasants (Durham, United States of America), A. Bedoya (Durham, United States of America), R. Kundich (Durham, United States of America), A. Reihman (Durham, United States of America), K. Welty-Wolf (Durham, United States of America), R. Tighe (Durham, United States of America)
| |
Interstital lung disease rates and risk factors in a UK lung cancer screening trial
T. Mikolasch (London, United Kingdom), M. Ruparel* (London, United Kingdom), J. Dickson (London, United Kingdom), C. Horst (London, United Kingdom), S. Tisi (London, United Kingdom), S. Quaife (London, United Kingdom), N. Navani (London, United Kingdom), M. Taylor (London, United Kingdom), A. Ahmed (London, United Kingdom), P. Shaw (London, United Kingdom), S. Burke (London, United Kingdom), M. Soo (London, United Kingdom), A. Bhowmik (London, United Kingdom), J. Porter (London, United Kingdom), S. Janes (London, United Kingdom)
| |
A simple prognostic tool for idiopathic pulmonary fibrosis (IPF)
T. Gille (Bobigny, France), K. Levand (Bobigny, France), M. Boubaya (Bobigny, France), L. Moya (Bobigny, France), G. Bertrand (Bobigny, France), Z. Carton (Bobigny, France), C. Planès (Bobigny, France), D. Valeyre (Bobigny, France), P. Brillet (Bobigny, France), H. Nunes (Bobigny, France)
| |
Does body mass index have prognostic significance for patients with idiopathic pulmonary fibrosis?
N. Mogulkoc (Izmir, Turkey), M. Sterclova (Prague, Czech Republic), V. Müller (Budapest, Hungary), J. Kus (Warsaw, Poland), M. Hajkova (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Janotova (Brno, Czech Republic), M. Vasakova (Prague, Czech Republic)
| |
Myositis-specific antibodies in a cohort of idiopathic interstitial pneumonias with suggestive morphologies.
L. De Sadeleer (Leuven, Belgium), S. Verleden (Leuven, Belgium), E. De Langhe (Leuven, Belgium), N. Bodart (Leuven, Belgium), A. Vigneron (Leuven, Belgium), X. Bossuyt (Leuven, Belgium), B. Vanaudenaerde (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
| |